Novavax Submits Final Data Packages To U.S. FDA As Prerequisite To Emergency Use Authorization Application Request For COVID-19 Vaccine

Published by
The Street

By PR Newswire GAITHERSBURG, Md., Dec. 31, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has completed submission of the final data package, including the complete chemistry, manufacturing and controls module, to fulfill the prerequisites for emergency use authorization (EUA) application request to the U.S. Food and Drug Administration (FDA) for NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™…

Read More

Popular Posts
Advertisement
Calendar
March 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031